CG Oncology: Passing A Red Line For What I Would Call A Reasonable Valuation (Rating Downgrade)

Galzus Research3.2K FollowersFollow5ShareSavePlay(9min)CommentsSummaryCG Oncology has seen significant stock appreciation but now enters a holding pattern with reduced near-term upside potential.Cretostimogene grenadenorepvec remains the lead asset, targeting non-metastatic bladder cancer with pivotal data and a BLA submission expected in 2025-2026.A key upcoming catalyst is the PIVOT-006 topline readout, the first randomized registrational study in intermediate-risk non-muscle invasive bladder cancer.With a strengthened balance sheet and recent fundraising, CGON projects a cash runway extending into the first half of 2029. Octavian Lazar/iStock via Getty Images Topline Summary and Update When I last took a look at CG Oncology (CGON), I reaffirmed a cautious "Buy" sentiment even though the stock had been on the rise for some time. Since then, the stockThis article was written byGalzus Research3.2K FollowersFollowI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.